Transcept Pharmaceuticals Inc, Richmond, Calif, will participate in a panel
focused on middle-of-the-night (MOTN) insomnia at the Natixis Bleichroeder
"Hidden Gems" Healthcare Conference in New York, October 8.
The panel will focus on MOTN, a type of insomnia characterized by people who
wake up in the middle of the night and have trouble returning to sleep.
Transcept’s pipeline drug, Intermezzo, a low-dose formulation of Zolpidem,
recently underwent Phase 3 testing, and is being designed to specifically
target MOTN. 
A recent survey estimated that up to 35% of adults in the United States
suffer from this and related sleep disorders, said Glenn Oclassen, president
and CEO of Transcept and a member of the panel. “Despite this large patient
population, there is no pharmaceutical agent currently approved to treat
this common sleep problem,” he added.
The company plans to file the Intermezzo NDA with the US Food and Drug
Administration (FDA) in 2008.
To read the full news release, click here.